Print Page   |   Contact Us   |   Your Cart   |   Sign In
Sign In

Forgot your password?

Haven't registered yet?

Breaking News
News & Press: Daily Updates

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivati

Wednesday, October 05, 2016   (0 Comments)

The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks.


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2016. Sponsorship does not imply endorsement by OSAP of a company's products or services.